Tepezza (teprotumumab) is a monoclonal antibody medication which was FDA-approved in the US in the spring of 2020. Tepezza is the only medication which has been shown to permanently improve inflammation, proptosis, and double vision in patients with thyroid eye disease.
What is Tepezza?
Patient with active, inflammatory TED.
Who is a candidate for Tepezza?
Currently, patients who have active thyroid eye disease and meet specific clinical criteria (clinical activity score >4) are a candidate for the drug. Tepezza may work better the earlier you start the drug, so do not delay getting a formal evaluation!
What are common side effects?
Tepezza is not for patients with inflammatory bowel disease (Crohn’s or ulcerative colitis). The most common side effects included high blood sugar, muscle spasm, tinnitus (ringing ears), and gastrointestinal upset.